NFID Announces 2022-2023 Board of Directors

Bethesda, MD (July 7, 2022)—The National Foundation for Infectious Diseases (NFID) is pleased to announce the 2022-2023 NFID Board of Directors and updated slate of officers, including President Patricia (Patsy) A. Stinchfield, RN, MS, CPNP; President-Elect Jeffery A. Goad, PharmD, MPH; and Vice President Kathleen M. Neuzil, MD, MPH.

A nurse practitioner specializing in pediatric infectious diseases, Patricia (Patsy) A. Stinchfield, RN, MS, CPNP, currently has an affiliate faculty position at the University of Minnesota School of Nursing. Prior to her retirement in July 2021, she served as senior director of infection prevention and control at Children’s Minnesota, where she remains on professional staff. Throughout her 45-year nursing career, she has focused on the prevention of infectious diseases and is a frequent national speaker on vaccine-preventable diseases, vaccine communication, vaccinology, and vaccination of healthcare professionals.

“I am concerned about the misinformation and disinformation we have seen develop around COVID-19 vaccines and the resulting impact on all vaccination rates,” says Stinchfield. “As NFID president, I hope to collaborate with other partner organizations to use our collective expertise to speak with one strong voice. It is an honor to be moving into the role of NFID president and I am dedicated to working with my respected colleagues to achieve our vision of healthier lives through the effective prevention and treatment of infectious diseases.”

Stinchfield is a widely recognized infectious disease specialist, having served as the first nurse voting member of the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) where she continues to serve as a liaison member for the National Association of Pediatric Nurse Practitioners and serves on the Influenza and Schedule Work Groups. She was the hospital incident commander for the COVID-19 response at Children’s Minnesota, and led the responses during the H1N1 influenza and the 2017 measles outbreaks. Stinchfield was lead author of a 2020 NFID report on Vitamin A for the Management of Measles in the US.

Kathleen M. Neuzil, MD, MPH, is the Myron M. Levine Professor in Vaccinology, professor of medicine and pediatrics, and director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine. An internationally recognized research scientist and advocate in the field of vaccinology, she has played a central role in the domestic and global response to COVID-19. Throughout her career, she has conducted clinical and epidemiologic studies on vaccine-preventable diseases including influenza, rotavirus, human papillomavirus, Japanese encephalitis, and typhoid. As a co-principal investigator of the National Institutes for Health-funded Leadership Group for the Vaccine and Treatment Evaluation Unit network, Dr. Neuzil is part of the strategic team evaluating COVID-19 vaccines and therapeutics in the US. She also directs the Typhoid Vaccine Acceleration Consortium (TyVAC), with the goal of accelerating the introduction of typhoid conjugate vaccines into low-resource countries. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and the prestigious National Academy of Medicine.

NFID President-Elect Jeffery A. Goad, PharmD, MPH, is a tenured professor of pharmacy practice and associate dean of academic affairs at Chapman University School of Pharmacy. For more than 20 years, he has maintained an active practice in travel medicine and immunization services.

Other new members of the NFID Board of Directors include Jean-Venable (Kelly) R. Goode, PharmD, of Virginia Commonwealth University, and Kathleen H. Harriman, PhD, MPH, RN, of the California Department of Public Health. Monica M. Farley, MD, of Emory University School of Medicine has been re-elected to serve an additional three-year term.

Jean-Venable (Kelly) R. Goode, PharmD, is professor and director of the Community-Based Pharmacy Residency Program at Virginia Commonwealth University. She is a credentialed community-based pharmacist practitioner at Daily Planet Health Services, a federally qualified health center that provides services to anyone regardless of their housing or insurance status. She developed innovative pharmacist patient care programs within a patient-centered medical home, including leading the Vaccines for Children and Vaccines for Adult Programs. Dr. Goode is a liaison member of the National Vaccine Advisory Committee and a former president of the American Pharmacists Association and Virginia Pharmacists Association.

 

Kathleen H. Harriman, PhD, MPH, RN, joined the California Department of Public Health (CDPH) in 2007 as the chief of the Vaccine Preventable Disease Epidemiology Section and is now a retired annuitant working on the COVID-19 response. Prior to CDPH, she worked for 15 years as a communicable disease epidemiologist at the Minnesota Department of Health, including supervising the statewide infection control program. In addition to COVID-19, she has worked on many communicable disease outbreaks including SARS, H1N1 influenza, measles, mumps, and meningococcal disease. She also has worked as a pediatric emergency room nurse and as an infection preventionist at Children’s Minnesota. Dr. Harriman served as a voting member of ACIP from 2012-2016.

A complete list of the 2022-2023 NFID Board of Directors is below. This esteemed group of public health leaders officially began responsibilities on July 1, 2022. As the governing body, the Board of Directors establishes the strategic direction for NFID, ensures that annual goals are met, and provides financial oversight.

The NFID Board of Directors also expresses its appreciation to outgoing Past President Joseph A. Bocchini, Jr., MD, of Willis-Knighton Health System, for his leadership over many years including during the COVID-19 pandemic, and outgoing Director Lisa S. Ipp, MD, of Weill Cornell Medicine, New York-Presbyterian for their contributions to NFID.

2022-2023 NFID Board of Directors

• Cristina Cassetti, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NFID Federal Liaison)
• Sara E. Cosgrove, MD, MS, Johns Hopkins University School of Medicine
• Tamera Coyne-Beasley, MD, MPH, The University of Alabama at Birmingham
• Monica M. Farley, MD, Emory University School of Medicine
• Jeffery A. Goad, PharmD, MPH (NFID President-Elect), Chapman University School of Pharmacy
• Jean-Venable R. Goode, PharmD, Virginia Commonwealth University
• Kathleen H. Harriman, PhD, MPH, RN, California Department of Public Health
• Orin S. Levine, PhD, Bill & Melinda Gates Foundation (Former)
• Ruth Lynfield, MD (NFID Secretary), Minnesota Department of Health
• Julie Morita, MD, Robert Wood Johnson Foundation
• Kathleen M. Neuzil, MD, MPH (NFID Vice President), Center for Vaccine Development and Global Health, University of Maryland School of Medicine
• Kevin Rooney (NFID Treasurer), Beacon Consulting Group
• S. Shaefer Spires, MD, Duke University Hospital
• Patricia A. Stinchfield, RN, MS, CPNP (NFID President), University of Minnesota School of Nursing
• Patricia N. Whitley-Williams, MD (NFID Immediate Past-President), Rutgers Robert Wood Johnson Medical School

Ex-Officio:

• Marla Dalton, PE, CAE, NFID Executive Director & CEO
• William Schaffner, MD, NFID Medical Director

About the National Foundation for Infectious Diseases

Founded in 1973, the National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating the public and healthcare professionals about the burden, causes, prevention, diagnosis, and treatment of infectious diseases across the lifespan. For additional information, visit www.nfid.org.

Contact: Diana Olson, National Foundation for Infectious Diseases, dolson@nfid.org, (301) 656-0003×140